Cyclocopacamphan-12-ol (epimer A) is a low-profile sesquiterpene alcohol reported in vetiver oil, especially in South Indian and Java-style profiles. The evidence base available in open sources is much stronger for identity, chromatography, and occurrence than for isolated pharmacology or safety. For AromaForge, this constituent is best described as a vetiver odor-marker and compositional fingerprint compound with explicit evidence gaps rather than as a standalone active.
Chemical identity and composition
PubChem returns Cyclocopacamphan-12-ol, epimer a as CID 91749519 with formula C15H24O and a stereochemistry-specific InChIKey distinct from the generic Cyclocopacamphan-12-ol record. NIST also lists Cyclocopacamphan-12-ol as a parent record with stereoisomer pages for epimers A and B, reinforcing that the archive should keep the epimer label explicit rather than collapsing the constituent into a non-specific alcohol record.
Aroma and practical use
- Use the recorded woody, dry, earthy, vetiver-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
vetiver compositional marker
A PubMed abstract on vetiver oils from four south Indian locations named cyclocopacamphan-12-ol epimers A and B among the important compounds that impart characteristic vetiver odor.
Measured: odor-marker and constituent identification
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
chromatographic identity support
NIST lists Cyclocopacamphan-12-ol as a parent record with stereoisomers including epimer a and provides gas-chromatography data pages for the compound family, supporting analytical identification rather than biological activity claims.
Measured: stereoisomer recognition and retention-index support
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific dermal limit, IFRA restriction, or human safety study was verified for cyclocopacamphan-12-ol epimer A in this research pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the available public literature is dominated by analytical vetiver-oil composition work, safety framing should stay at the parent-oil level unless stronger compound-specific data surface.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The current evidence does not support making pharmacological or therapeutic claims for the isolated epimer.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (7)
- No isolated pharmacology papers specific to cyclocopacamphan-12-ol epimer A were verified in the reviewed open sources.
- No human clinical evidence was located.
- No stable public CAS number was verified for the epimer-specific record, so the CAS field remains null.
- Follow-up web search (2026-07-11) found only oil-level vetiver safety commentary (general aromatherapy sources describe vetiver essential oil overall as non-toxic, non-irritating, non-sensitizing; a separate SCCS/RIFM assessment exists for Acetylated Vetiver Oil specifically, a different derivative) and no epimer-specific RIFM assessment or IFRA Standard. sensitizing:true is left unchanged as an unverified constituent-class placeholder rather than a citation-backed value; it is not contradicted or confirmed by the oil-level statement found.
- Re-check web search (2026-07-13) confirmed cyclocopacamphan-12-ol as a 1.0-6.7% vetiver-oil constituent (NIST) and found IFRA/SCCS dermal-limit data only for Acetylated Vetiver Oil (a distinct derivative, e.g. IFRA Standard Amendment 49, up to 0.10% in leave-on products), not for cyclocopacamphan-12-ol or vetiver oil itself. No epimer-specific RIFM assessment or IFRA Standard exists. The prior placeholder dermal_limit_pct (20%) and sensitizing (true) values had no locatable constituent-specific citation and were corrected to null rather than left as unsupported values.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.